U.S. markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.68 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.58 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.39 (-0.61%)
     
  • Gold

    1,777.30
    +10.50 (+0.59%)
     
  • Silver

    26.04
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1980
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • GBP/USD

    1.3842
    +0.0058 (+0.42%)
     
  • USD/JPY

    108.7500
    +0.0340 (+0.03%)
     
  • BTC-USD

    62,013.30
    -1,808.37 (-2.83%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

Antares Pharma's Earnings: A Preview

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Antares Pharma (NASDAQ:ATRS) releases its next round of earnings this Tuesday, March 02. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.

What Are Earnings, Net Income, And Earnings Per Share?

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

Wall Street expects EPS of $0.03 and sales around $40.75 million. Antares Pharma earnings in the same period a year ago was $0.03 per share. Quarterly sales came in at $37.84 million.

What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter?

Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.

View more earnings on ATRS

The analyst consensus estimate would represent 0% change in company's EPS figure. Revenue would be have grown 7.69% from the same quarter last year. The company's reported EPS has stacked up against analyst estimates in the past like this:

EPS Estimate

0.02

0

0

0

EPS Actual

0.03

0.01

-0.01

0.03

Revenue Estimate

35.67 M

30.38 M

30.78 M

32.28 M

Revenue Actual

40.00 M

32.38 M

33.08 M

37.84 M

Stock Performance

Shares of Antares Pharma were trading at $4.25 as of February 26. Over the last 52-week period, shares are up 42.77%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Antares Pharma is scheduled to hold the call at 08:30:00 ET and can be accessed here.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.